Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03677739
Other study ID # Pro2018001697
Secondary ID NCI-2018-01741Pr
Status Recruiting
Phase N/A
First received
Last updated
Start date June 3, 2019
Est. completion date December 1, 2024

Study information

Verified date January 2024
Source Rutgers, The State University of New Jersey
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial studies how well Young Melanoma Family Facebook intervention or Healthy Lifestyle Facebook intervention works in improving skin examination in participants with melanoma and their families. Young Melanoma Family Facebook intervention or Healthy Lifestyle Facebook intervention may help improve total cutaneous examinations, skin self-examinations, and sun protection among first degree relatives of young onset participants and the participants themselves.


Description:

PRIMARY OBJECTIVES: I. To examine the efficacy of the Young Melanoma Family Facebook intervention versus the Healthy Lifestyle Facebook intervention on total cutaneous exam (primary outcome), skin self-exam frequency and comprehensiveness, and sun protection practices (secondary outcomes) of first degree relatives (FDRs) of young melanoma survivors. SECONDARY OBJECTIVES: I. To examine the efficacy of the Young Melanoma Family Facebook intervention on patients? skin self-exam frequency and comprehensiveness and sun protection habits. II. To examine the mechanisms of intervention efficacy. OUTLINE: PHASE I: Researchers refine content for the Facebook intervention condition and conduct usability testing. PHASE II: Participants are randomized to 1 of 2 arms. ARM I: Participants join a secret Young Melanoma Family Facebook Group and view post messages focusing on skin cancer for 12 weeks. ARM II: Participants join a secret Healthy Lifestyle Facebook Group and view post messages focusing on healthy lifestyle for 12 weeks. PHASE III: Dissemination planning. After completion of study, participants are followed up at 6 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 1160
Est. completion date December 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - PATIENT: Diagnosed with stage 0-3 melanoma in the last 5 years - PATIENT: Age at diagnosis 18-39 years - PATIENT: Completed treatment at least 3 months previously - PATIENT: Recruited from New Jersey or California State Cancer Registry or MD Anderson Cancer Center - PATIENT: Does not have a concurrent cancer diagnosis - PATIENT: Able to speak and read English - PATIENT: Access to computer, internet, and has a Facebook account - PATIENT: At least one family member consents - FDR: Current age 18-80 years - FDR: Does not have a personal history of melanoma - FDR: Able to speak and read English - FDR: Access to computer, internet, and has a Facebook account - FDR: Has only one FDR with melanoma (patient) - FDR: Has not had a total cutaneous examination (TCE) in the past 3 years, has done skin self-exam (SSE) fewer than three times in the past year, OR has a sun protection habits average score less than or equal to 4 (?often?) - FDR: Patient consents Exclusion Criteria: - Physical Activity Readiness Questionnaire (Thomas, et. al., 1992): This 7-item scale will be used to screen out individuals who will need to consult a physician for medical clearance before engaging in physical activity. If a participant checks off any of the items, the investigators will ask for a physician clearance before consenting to study

Study Design


Related Conditions & MeSH terms

  • Clinical Stage 0 Cutaneous Melanoma AJCC v8
  • Clinical Stage I Cutaneous Melanoma AJCC v8
  • Clinical Stage IA Cutaneous Melanoma AJCC v8
  • Clinical Stage IB Cutaneous Melanoma AJCC v8
  • Clinical Stage II Cutaneous Melanoma AJCC v8
  • Clinical Stage IIA Cutaneous Melanoma AJCC v8
  • Clinical Stage IIB Cutaneous Melanoma AJCC v8
  • Clinical Stage IIC Cutaneous Melanoma AJCC v8
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • First Degree Relative
  • Melanoma
  • Pathologic Stage 0 Cutaneous Melanoma AJCC v8
  • Pathologic Stage I Cutaneous Melanoma AJCC v8
  • Pathologic Stage IA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IB Cutaneous Melanoma AJCC v8
  • Pathologic Stage II Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIC Cutaneous Melanoma AJCC v8
  • Pathologic Stage III Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
  • Skin Neoplasms

Intervention

Other:
Informational Intervention
Receive information focusing on skin cancer
Informational Intervention
Receive information on healthy lifestyle
Survey Administration
Ancillary studies

Locations

Country Name City State
United States MD Anderson Cancer Center Houston Texas
United States Rutgers Cancer Institute of New Jersey New Brunswick New Jersey

Sponsors (2)

Lead Sponsor Collaborator
Rutgers, The State University of New Jersey National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Mediator analyses - Intervention Group Mediator analyses examining normative influences on the effects of intervention group on TCE, SSE and sun protection. 6 months
Other Mediator analyses - (Relatives) Mediator analyses examining family and peer support and discussion on the effects of intervention group on TCE, SSE and sun protection. 6 months
Other Mediator analyses - Intervention Group - Risks Mediator analyses examining risk on the effects of intervention group on TCE, SSE and sun protection. 6 months
Other Mediator analyses - Intervention Group - Benefits Mediator analyses examining benefits on the effects of intervention group on TCE, SSE and sun protection. 6 months
Other Mediator analyses - Intervention Group - Barriers Mediator analyses examining barriers on the effects of intervention group on TCE, SSE and sun protection. 6 months
Other Mediator analyses - Intervention Group - Self-efficacy Mediator analyses examining self-efficacy on the effects of intervention group on TCE, SSE and sun protection. 6 months
Other Mediator analyses - Intervention Group - Change Strategies Mediator analyses examining use of change strategies on the effects of intervention group on TCE, SSE and sun protection. 6 months
Other Moderator analysis - Melanoma Risk Factors Moderator analysis Melanoma risk factors will explore whether the intervention group is more effective for subsets of FDRs. 6 months
Other Moderator analysis - month of the year enrolled Moderator analysis month of the year enrolled will explore whether the intervention group is more effective for subsets of FDRs. 6 months
Other Moderator analysis - Residential Latitude Moderator analysis residential latitude will explore whether the intervention group is more effective for subsets of FDRs. 6 months
Other Moderator analysis - Sex Moderator analysis sex will explore whether the intervention group is more effective for subsets of FDRs. 6 months
Other Moderator analysis - patient disease stage Moderator analysis patient disease stage will explore whether the intervention group is more effective for subsets of FDRs. 6 months
Other Moderator analysis relationship to patient Moderator analysis relationship to patient will explore whether the intervention group is more effective for subsets of FDRs. 6 months
Other Predictor - Engagement Facebook engagement including likes, comments- collected at the end of the group 6 months
Other Predictor - Social Network Use Social network use measured by self-reported frequency of use of popular social media sites 6 months
Primary Total cutaneous examination (TCE) Will be assessed as a binary response (yes/no) did participant have one At 6 months
Secondary Skin Self-exam (Relatives) Skin self-exam of first degree relatives will be analyzed as a binary (yes/no) Response did participant complete one Yes/No Up to 5 years
Secondary Skin self-exam - Count Response (Relatives) Skin self exam of first degree relatives count response will be calculated as frequency/month. Frequency per month reported as a number. Up to 5 years
Secondary Skin self-exam - Comprehensiveness (Relatives) : Skin self-exam of first degree relatives comprehensiveness calculated as total # body parts examined during the skin self-exam Up to 5 years
Secondary Sun Protection Habits (Relatives) sun protection habits score of first degree relatives will be calculated as continuous variables using the Sun protection behaviors scale (Glanz, et. al., 2002) which measures 5 behaviors (regular outdoor use of: sunscreen, hat, shade, long-sleeved shirt, sunglasses). Up to 5 years
Secondary Skin self-exam - Count Response (Patients) Skin self-exam of patients count response calculated as (frequency/month). Frequency per month reported as a number Up to 5 years
Secondary Skin self-exam - Comprehensiveness (Patients) Skin self-exam of patients comprehensiveness calculated as total # body parts examined during the skin self-exam. Up to 5 years
Secondary Sun Protection Habits (Patients) sun protection habits score of patients will be calculated as continuous variables using the Sun protection behaviors scale (Glanz, et. al., 2002) which measures 5 behaviors (regular outdoor use of: sunscreen, hat, shade, long-sleeved shirt, sunglasses). Up to 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05039801 - IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Phase 1
Active, not recruiting NCT02224781 - Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Phase 3
Active, not recruiting NCT04940299 - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Phase 2
Recruiting NCT04990726 - Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
Active, not recruiting NCT04967196 - Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma Phase 1
Recruiting NCT03554083 - Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma Phase 2
Recruiting NCT04593277 - Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study N/A
Active, not recruiting NCT03033576 - Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma Phase 2
Suspended NCT04708418 - A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma Phase 2
Active, not recruiting NCT03816332 - Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Phase 1
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Recruiting NCT04314401 - National Cancer Institute "Cancer Moonshot Biobank"
Active, not recruiting NCT02506153 - Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Phase 3
Recruiting NCT05764395 - Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors Phase 2
Active, not recruiting NCT04516122 - Bone Loss in Melanoma Survivors Receiving Immunotherapy
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT01989585 - Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma Phase 1/Phase 2
Recruiting NCT06265285 - Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Phase 2
Recruiting NCT05098210 - Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer Phase 1
Completed NCT04067960 - Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer Early Phase 1